title: Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.
abstract: BACKGROUND
  To report three cases of early choroidal neovascularization (CNV) bridging after ranibizumab treatment.
  
  
  METHODS
  Three patients with two separated foci of CNV secondary to age-related macular degeneration (ARMD), pathologic myopia and multifocal choroiditis were treated with monthly injections of ranibizumab por a period of 3 months.
  
  
  RESULTS
  All three cases showed early coalescence across the fovea of the two neovascular foci, already 1 month after the first ranibizumab injection. Best-corrected visual acuity (BCVA) decreased in the three cases more than 20 letters due to early foveal involvement.
  
  
  CONCLUSIONS
  Two different foci of CNV show a great tendency to decrease patients' vision because of neovascular bridging with foveal implication.
authors.affiliation: Hospital Clínico Universitario San Carlos, Calle Profesor Martín Lagos s/n, Madrid, Spain. echejuan@yahoo.es
authors.forename: Juan
authors.initials: J
authors.lastname: Reche-Frutos
authors.forename: Cristina
authors.initials: C
authors.lastname: Calvo-Gonzalez
authors.forename: Juan
authors.initials: J
authors.lastname: Donate-Lopez
authors.forename: Julian
authors.initials: J
authors.lastname: Garcia-Feijoo
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002833:Choroiditis / Q000150:complications*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005584:Fovea Centralis / Q000473:pathology; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D047728:Myopia, Degenerative / Q000150:complications*; D009887:Ophthalmoscopy; D000069579:Ranibizumab; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab